ArticleRespiratory research2025
Quantitative analysis of chest computed tomography in alpha-1-antitrypsin deficiency.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Alpha-1-Antitrypsin and Folic Acid as Biomarkers for Glaucoma Risk.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChest quantitative computed tomography (QCT) has been used in clinical trials to monitor patients with alpha-1 antitrypsin deficiency (AATD). There is limited data on the use of quantitative computed tomography (QCT) to phenotype emphysema in AATD.
methodsData from patients with a reduced AATD serum level and/or at least one deficiency mutation, who underwent a chest CT scan at the Thoraxklinik, University of Heidelberg, between 03/2012 and 02/2024, were retrospectively analyzed. The patients were categorized into three groups based on their AAT serum levels: reduced to normal (> 70 mg/dl), moderate (41-70 mg/dl), and severe (≤ 40 mg/dl). The QCT analyses were performed using a fully automated quantitative CT software package (YACTA v2.9.4.98).
resultsIn this retrospective cohort study, 75 AATD patients were analysed, including 13 with reduced-to-normal AATD, 16 with moderate AATD and 46 with severe AATD. The mean age was 54.3 ± 14.7 years with no differences between groups. Significant differences in pack-years (PY) were found: reduced to normal 14.9 ± 17.2, moderate 39.4 ± 31.9 and severe 15.1 ± 14.6 (p < 0.001). There were no differences in predicted FEV1% (54.1 ± 28.9%). QCT emphysema parameters showed a decrease in mean lung density and 15th percentile with lower serum levels (p < 0.05 for each), but no differences in global emphysema index (EI). A lobar-specific analysis, revealed that the reduced-to-normal and moderate AATD groups exhibited upper-lobe predominant emphysema. In contrast, the severe AATD group showed basal-predominant emphysema with maxima in the middle lobe and lingula. Additionally, a binary logistic regression analysis identified age (CI 1.01-1.12, p = 0,024) and lower of AATD serum levels (CI 0.92-0.98, p = < 0.001) as significant indicators for an emphysema pattern that was predominantly localized in the middle lobe and lingula.
conclusionThe study provides new insights into the distribution of emphysema, with lobar-specific quantitative analysis challenging the existing paradigm that emphysema in severe AATD is most pronounced in the lower lobes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.